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Marijuana and its main psychotropic ingredient D
9-tetrahydrocannabinol (THC) exert a plethora of psychoactive effects
through the activation of the neuronal cannabinoid receptor type 1 (CB1), which is expressed by different neuronal
subpopulations in the central nervous system. The exact neuroanatomical substrates underlying each effect of THC
are, however, not known. We tested locomotor, hypothermic, analgesic, and cataleptic effects of THC in conditional
knockout mouse lines, which lack the expression of CB1 in different neuronal subpopulations, including principal brain
neurons, GABAergic neurons (those that release c aminobutyric acid), cortical glutamatergic neurons, and neurons
expressing the dopamine receptor D1, respectively. Surprisingly, mice lacking CB1 in GABAergic neurons responded to
THC similarly as wild-type littermates did, whereas deletion of the receptor in all principal neurons abolished or
strongly reduced the behavioural and autonomic responses to the drug. Moreover, locomotor and hypothermic effects
of THC depend on cortical glutamatergic neurons, whereas the deletion of CB1 from the majority of striatal neurons
and a subpopulation of cortical glutamatergic neurons blocked the cataleptic effect of the drug. These data show that
several important pharmacological actions of THC do not depend on functional expression of CB1 on GABAergic
interneurons, but on other neuronal populations, and pave the way to a refined interpretation of the pharmacological
effects of cannabinoids on neuronal functions.
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Introduction
Cannabinoids are a class of pharmacological compounds
that comprise derivatives of the plant Cannabis sativa
(marijuana) and represent one of the oldest known sources
of psychotropic drugs [1,2]. D
9-tetrahydrocannabinol (THC)
is the prototypical plant-derived psychoactive cannabinoid
and the main cause of the psychotropic effects of marijuana,
which is the most widespread illicit drug in the world.
Administration of cannabinoids to animals and humans
induces a complex pattern of behavioural effects, which can
be analyzed in laboratory settings [3]. In particular, in mice,
cannabinoids produce a speciﬁc array of effects in the same
dose range and within the same time frame. These effects,
consisting of hypolocomotion, hypothermia, antinociception,
and catalepsy (impaired ability to initiate movements),
represent the so-called ‘‘tetrad model’’ of cannabimimetic
activity [3–5]. Despite the fact that the ‘‘tetrad’’ of effects does
not exhaustively represent the myriad cannabinoid behav-
ioural and autonomic actions, it is one of the best available
measures of cannabimimetic activity of drugs and has been
extensively used to identify and classify cannabinoid com-
pounds [3,4]. The psychoactive effects of cannabinoids are
mediated by the cannabinoid receptor type 1 (CB1) and, in
particular, the tetrad effects of THC are abolished in mutant
mice lacking the expression of CB1 [6,7] and are blocked by
CB1 antagonists [5,8,9]. Moreover, psychotropic effects of
marijuana were shown to be attenuated by blockade of CB1
receptors in humans, conﬁrming the central importance of
these receptors in the pharmacology of psychotropic canna-
binoids [10].
CB1 is a seven-transmembrane G protein-coupled receptor
expressed at very high levels in the central nervous system
and at lower levels in peripheral tissues [11,12]. Together with
CB2 cannabinoid receptors, CB1 is the molecular target of
speciﬁc endogenous lipid signalling molecules, the endocan-
nabinoids [13–15]. Cannabinoid receptors, endocannabinoids
and the enzymatic machinery for endocannabinoid synthesis
and degradation constitute the endocannabinoid system,
which is involved in several physiological and pathophysio-
logical processes such as, among many others, retrograde
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PLoS BIOLOGYsignalling at neuronal synapses [16,17], memory processing
[15,17], pain perception [15,18,19], regulation of locomotion
[15,18], and inﬂammation [15,20,21]. In the brain, the
expression of CB1 correlates with the psychotropic effects
of cannabinoids [11,22]. However, the neuronal mechanisms
and the neuronal circuitries responsible for these effects have
not yet been clariﬁed. In the brain, where THC and other
cannabinoids exert most of their behavioural effects, CB1
receptors are expressed at different levels in different
neuronal subpopulations. In particular, CB1 protein and
mRNA are present at very high levels in cortical GABAergic
interneurons (those that release c aminobutyric acid [GA-
BA]), where they mediate cannabinoid-dependent inhibition
of GABA release [17,23,24]. However, CB1 receptors are also
expressed in other neuronal subpopulations, including,
among others, glutamatergic cortical principal neurons [24–
30]. Given the extraordinary high expression of CB1 on
GABAergic interneurons, the modulation of the activity of
these neurons is generally believed to mediate most of the
effects of exogenously administered and endogenously
released cannabinoids [23]. However, due to the lack of
suitable experimental tools, this concept has not yet been
investigated in vivo.
With the advent of conditional mutagenesis techniques,
which are aimed also at obtaining speciﬁc deletion of genes in
particular cell types [31,32], it is now possible to address
directly the involvement of different neuronal populations in
the pharmacological effects of cannabinoids. We used
recently generated conditional mutant mice for the CB1
receptor, bearing a deletion of the CB1 gene in principal
neurons (deﬁned as projecting neurons as opposed to
interneurons, independently of their neurochemical charac-
teristics, normally expressing Ca
2þ/calmodulin-dependent
kinase IIa [CaMKIIa] [33,34]), in cortical glutamatergic
neurons, and in GABAergic neurons [26,27]. Furthermore,
we produced a new mouse mutant line where the Cre-
mediated deletion of the CB1 gene is driven by the regulatory
sequences of the D1 dopamine receptor. All of these
conditional CB1 mouse mutants were tested in the ‘‘tetrad’’
battery of THC effects. The results indicate that the typical
pharmacological effects of cannabinoids rely on complex
anatomical substrates and that, at odds with previous
concepts, GABAergic interneurons appear not to be involved
in these effects.
Results
Locomotor, Hypothermic, Analgesic, and Cataleptic
Effects of THC Depend on CB1 Receptors
The ‘‘tetrad’’ effects of THC were shown to depend on the
expression of CB1 receptors, because these effects are
abolished in CB1-null mutant mice and are blocked by CB1
antagonists [5,7–9]. However, discrepancies in the phenotype
of CB1-null mutant lines were observed in different exper-
imental setups, likely due to differences of test conditions and
genetic background of the mice [6,7]. To verify that the
‘‘tetrad’’ effects of THC fully depend on CB1 expression
under our experimental conditions and in our strain of CB1-
null mutants, we ﬁrst performed a dose-response (0, 1, 3, and
10 mg THC/kg mouse body weight [mg/kg]) study of these
effects of THC in mice and then used the dose of 10 mg/kg on
CB1
 /  mice and their littermates CB1
þ/þ [35]. The results
clearly showed that THC dose-dependently exerts the
‘‘tetrad’’ effects in our experimental conditions (Figure 1A–
1D) and that the deletion of CB1 does not alter per se the
observed basal conditions of vehicle-treated animals, but fully
abolished the effects of THC (Figure 1E–1H; interaction
genotype 3 treatment, F1,34 . 9.6, p , 0.004).
Generation of Conditional Mutant Mice Lacking CB1 in
Dopamine Receptor D1-Expressing Neurons
To dissect the neuronal circuits involved in the effects of
THC, we used available conditional mutants lacking CB1 in
speciﬁc neuronal populations [26,27]. However, these lines
present overlapping patterns of deletion, which might limit
the interpretation of the results. For instance, GABA-CB1
 / 
mice and CaMK-CB1
 /  mice both lack CB1 expression in
striatal medium spiny neurons (MSNs) [27]. As a consequence,
possible differences in the effects of THC in these two mouse
lines (see below) could be difﬁcult to interpret. Therefore, to
obtain a further speciﬁc deletion of CB1 in striatal neurons,
we crossed CB1
f/f mice with a transgenic mouse line where
Cre recombinase is expressed under the control of the
regulatory sequences of dopamine receptor D1 (D1-Cre)
[36,37] to generate D1-CB1
 /  mice (Figure 2). Mutant mice
were fertile and did not show any obvious phenotypic
alteration. In situ hybridization (ISH) analysis of CB1
expression revealed the expected pattern of recombination,
with CB1 mRNA absent in the majority of striatal neurons but
still expressed in other brain regions (Figure 2A).
Overall, in D1-CB1
 /  mice, the great majority of MSNs of
caudate putamen do not show CB1 expression, leaving only
27.9% of CB1 expression in the caudate putamen (total CB1-
positivecells:D1-CB1
þ/þ,13.9 61.3cells/ﬁeld versus D1-CB1
 / ,
3.9 6 0.2 cells/ﬁeld; Figure 2A, 2B, and 2B9), which is in
agreement with the expected recombination pattern induced
by Cre recombinase under the control of D1 regulatory
sequences [36]. In the ventral striatum, owing to the very low
levels of expression of CB1 mRNA [24,25], it is difﬁcult to
quantify the loss of CB1 in mutant mice (Figure 2A). An
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Author Summary
Marijuana and its main psychoactive component, THC, exert a
plethora of behavioural and autonomic effects on humans and
animals. Some of these effects are the cause of the widespread illicit
use of marijuana, while others might be involved in the potential
therapeutic use of this drug for the treatment of several neuronal
disorders. The great majority of these effects of THC are mediated by
cannabinoid receptor type 1 (CB1), which is abundantly expressed in
the central nervous system. The exact anatomical and neuronal
substrates of each action are, however, not clearly known at the
moment. We addressed this issue by using an advanced genetic
approach. Control and conditional mutant mice, lacking CB1
expression in defined neuronal subpopulations but not in others,
were treated with THC, and typical effects of the drug on motor
behaviour, pain, and thermal sensation were scored. Our results
show that different neuronal subpopulations mediate different
effects of THC and could lead to a refined interpretation of the
pharmacological actions of cannabinoids. Moreover, these data
might provide the rationale for the development of drugs capable of
selectively activating CB1 in specific neuronal subpopulations,
thereby better exploiting cannabinoids’ potential therapeutic
properties.evaluation based on dark-ﬁeld images of radioactive ISH for
CB1 mRNA (Figure 2C and 2C9) indicate that about 50% of
neuronsstillexpressCB1inthemutantmiceascomparedwith
wild-type littermates.
Dopamine D1 receptors are expressed not only in striatal
neurons, but also in other brain regions. In particular, Cre-
mediated recombination under the control of D1 regulatory
sequences occurs also in layer VI of the neocortex [36,37]. In
this region, CB1 mRNA is present both at high levels in
GABAergic interneurons [24] and at low levels in principal
glutamatergic neurons, coexpressed with the glutamatergic
neuronal marker vesicular glutamate transporter 1 [27] (and
unpublished observations). Due to the low levels of CB1
mRNA in these latter neurons and the fact that layer VI has a
Figure 1. Hypolocomotor, Hypothermic, Analgesic, and Cataleptic Effects of THC Depend on CB1 Receptors
(A–D) Dose-response of THC effects in wild-type mice. Effects of vehicle (n ¼ 16), 1 mg/kg (n ¼ 9), 3 mg/kg (n ¼ 9), and 10 mg/kg THC (n ¼ 10),
respectively, on the ‘‘tetrad’’ battery of tests consisting of (A) locomotor, (B) hypothermic, (C) analgesic, and (D) cataleptic effects. (E–H) THC effects
depend on CB1 receptor. Wild-type CB1
þ/þ and littermate CB1
 /  mice (i.e., null CB1 mutants) were tested for (E) locomotor, (F) hypothermic, (C)
analgesic, and (D) cataleptic effects of 10 mg/kg THC. Note the absence of any effect of the drug in CB1
 / . #, ##, ###; p , 0.05, p , 0.01, p , 0.001,
respectively, as compared to vehicle-treated animals (two-way ANOVA, followed by Dunnet’s post-hoc test). ***, p , 0.001 (two-way ANOVA, followed
by Newman-Keuls post-hoc test).
doi:10.1371/journal.pbio.0050269.g001
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Effects of THC in Conditional CB1 MutantsFigure 2. CB1 Receptor mRNA Distribution in D1-CB1
 /  Mice
(A) Bright-field photomicrographs showing CB1 mRNA expression in coronal brain sections of wild-type D1-CB1
þ/þ (left panels) and D1-CB1
 /  mice
(right panels).
(B–E9) Micrograph showing high magnifications of the details indicated in (A). (B and B9) Detail (corresponding to the areas depicted in (A)) of CB1
expression in the dorsolateral caudate putamen of D1-CB1
þ/þ (B) and D1-CB1
 /  (B9). Note the strong decrease in CB1-expressing cells in mutant mice.
(C and C9) Dark-field micrographs showing detail (corresponding to the areas depicted in (A)) of CB1 mRNA expression in the ventral striatum of D1-
CB1
þ/þ (C) and D1-CB1
 /  (C9).
(D andD9) Bright-field micrographs showing the expression of CB1 mRNA in layer VI of neocortex (corresponding to the areas depicted in (A)). Note the
similar number of cells expressing CB1 at high levels (intense concentration of silver grains) between genotypes and the decreased amount of cells
expressing CB1 at low levels in D1-CB1
 /  mice (see text for quantifications and details).
(E and E9) No evident difference in the levels of CB1 expression were observed in any other cortical regions, as exemplified in the basolateral amygdala.
(F and G) Micrographs showing CB1 mRNA (red staining) together with dopamine receptor D2 (silver grains) in the dorsal striatum of D1-CB1
þ/þ(F) and
D1-CB1
 /  mice (G). Note the reduction of CB1-expressing neurons and the presence of both dopamine receptor D2-positive and D2-negative CB1-
containing cells in D1-CB1
 /  mice (see text for quantifications and details). Filled arrows, single CB1-expressing neurons; open arrows, single D2-
expressing neurons; filled arrowheads, double CB1/D2 expressing neurons. Blue staining, toluidine blue nuclear counterstaining. Bars, 30 lm in B–E9,1 5
lm in F and G.
doi:10.1371/journal.pbio.0050269.g002
PLoS Biology | www.plosbiology.org October 2007 | Volume 5 | Issue 10 | e269 2357
Effects of THC in Conditional CB1 Mutantsrelatively small dimension, it is difﬁcult to assess the possible
deletion of CB1 by an observation of low-magniﬁcation
pictures (Figure 2A). Therefore, we performed a semi-
quantitative counting of the CB1-expressing neurons in layer
VI of the neocortex from images captured at high magniﬁ-
cation (see Materials and Methods). The results show that the
number of high CB1-expressing neurons is not changed in
D1-CB1
 /  mice (D1-CB1
þ/þ, 2.6 6 0.4 cells/ﬁeld versus D1-
CB1
 /  , 2.4 6 0.4 cells/ﬁeld, p . 0.05, n ¼ 5 sections per
genotype; Figure 2D and D9), whereas a signiﬁcant reduction
was observed in low CB1-expressing neurons (D1-CB1
þ/þ, 17.3
6 1.4 cells/ﬁeld versus D1-CB1
 /  , 7.7 6 1.3 cells/ﬁeld, p ,
0.01, n ¼ 5 sections; Figure 2D and 2D9). In other regions of
the brain, including forebrain cortical region (Figure 2A, 2E,
and 2E9), forebrain subcortical regions (Figure 2A), midbrain,
and hindbrain regions (Figure 2A), no evident alteration was
observed in the expression of CB1 in D1-CB1
 /  as compared
to wild-type D1-CB1
þ/þ.
More detailed analysis of CB1 expression in the caudate
putamen by double ISH revealed that CB1 is absent in the
great majority of non-D2 expressing neurons of mutant mice,
indicating the general deletion of the gene in neurons
expressing D1 (Figure 2F and 2G). However, in agreement
with the expected recombination pattern of D1-Cre mice
[36], a certain number of D2-expressing neurons appear to be
affected by the Cre-mediated recombination, because the
number of double CB1/D2-expressing neurons was decreased
in mutant mice. In fact, whereas CB1 is present in 8.3 6 0.9
cells/ﬁeld (corresponding to 36.6% 6 2.1% of total D2-
expressing neurons) in wild-type D1-CB1
þ/þ, this number
shows a 5-fold reduction in mutant D1-CB1
 /  (to 1.6 6 0.2
cells/ﬁeld, corresponding to 7.2% 6 0.6% of total D2-
expressing neurons; p , 0.0001 [Figure 2F and 2G]).
Conversely, not all the cells of caudate putamen that
maintained expression of CB1 in D1-CB1
 /  belong to the
D2-positive population. In fact, in wild-type D1-CB1
þ/þ mice,
single CB1-expressing neurons (i.e., non–D2-positive neu-
rons) were counted as 5.7 6 0.5 cells/ﬁeld, whereas their
presence is not abolished in D1-CB1
 /  (2.5 6 0.1 cells/ﬁeld).
These results indicate that non-D1, non-D2 neurons in the
caudate putamen keep their expression of CB1 in the mutant
mice. These neurons very likely belong to the population of
striatal GABAergic interneurons, which were shown to
contain CB1 mRNA [38].
Altogether, these data show that in D1-CB1
 /  mice, CB1
expression is strongly reduced in the striatum, with less than
30% of neurons still containing mRNA of the receptor in the
caudate putamen and approximately 50% of loss of CB1
expression in the ventral striatum. Of the remaining CB1-
positive neurons, one part belongs to the D2-positive
subpopulation of MSNs and the other part likely to striatal
GABAergic interneurons. Moreover, a signiﬁcant subgroup of
presumably glutamatergic projecting neurons of layer VI of
the neocortex shows deletion of CB1 in D1-CB1
 /  mice. The
recombination pattern of CB1 in D1-CB1
 /  mice is similar to
the known expression of D1 receptors. However, other cell
Figure 3. Graphic Representation of the Recombination Patterns of the
CB1 Gene in the Different Conditional Mutant Lines
Circles represent ‘‘domains‘‘ of recombination. Intersection areas
represent overlapping between the different recombination patterns.
CaMK-CB1
 /  mice (light blue) present the widest recombination of CB1,
which is partially overlapping with the one of GABA-CB1
 /  mice (red-
blue overlapping, i.e., principal striatal GABAergic neurons). GABA-CB1
 / 
mice (red) present a specific deletion of GABAergic neurons, which are
specific of this line concerning cortical GABAergic interneurons (non-
overlapping red area), but overlap with CaMK-CB1
 / and D1-CB1
 / mice
in the striatum. Glu-CB1
 /  recombination (green) fully overlap only with
CaMK-CB1
 /  (glutamatergic cortical neurons). D1-CB1
 /  mice (yellow)
share with GABA-CB1
 / and CaMK-CB1
 /  the deletion in the majority of
striatal neurons and with Glu-CB1
 /  and CaMK-CB1
 /  the deletion in
glutamatergic layer VI neocortical neurons.
Proportions of overlapping areas are not quantitative and are not
representative of cell numbers. Descriptive expression data are collected
from previous publications [27,28] and from the present study.
doi:10.1371/journal.pbio.0050269.g003
Table 1. Abbreviations Used to Identify the Different Mutants and Their Wild-Type Littermate Controls
Name of
Mutant Line
Name of Wild-Type
Littermate Controls
Regulatory Sequences
Driving Cre-Expression
Deletion of CB1 Maintained Expression
of CB1
CB1
 /  CB1
þ/þ — [35] Ubiquitous —
GABA-CB1
 /  GABA-CB1
þ/þ Dlx5/6 [27] GABAergic neurons Non-GABAergic neurons
CaMK-CB1
 /  CaMK-CB1
þ/þ CaMKIIa [26,44] Principal neurons Mostly cortical GABAergic
interneurons; cerebellum
Glu-CB1
 /  Glu-CB1
þ/þ NEX [27,45] Cortical glutamatergic neurons All other cell types
D1-CB1
 /  D1-CB1
þ/þ D1 dopamine receptor [36] Large part of striatal neurons;
part of glutamatergic neurons
of layer VI of neocortex
All other cell types
doi:10.1371/journal.pbio.0050269.t001
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Effects of THC in Conditional CB1 Mutantstypes might be affected too, such as dopamine receptor D2-
expressing MSNs, which are normally considered not to
coexpress D1 receptors [39,40]. However, other studies report
that the overlap between D1- and D2-expressing neurons in
the striatum might be higher than generally believed [41]. It is
not the aim of the present study to address this controversy.
However, for simplicity, in the following, we will refer to D1-
CB1
 /  mice as mice with a deletion of CB1 in ‘‘dopamine
receptor D1-expressing neurons’’. This is a given deﬁnition
and does not imply that Cre-mediated recombination of the
CB1 gene has occurred exclusively in D1-expressing neurons.
Behavioural Effects of THC in Different CB1 Mouse Mutant
Lines
The different mutant mouse lines used in this study, their
assigned nomenclature, and a general description of their
pattern of expression of CB1 receptor are listed in Table 1.
The different mutant lines present speciﬁc brain regions and
cell types carrying the Cre-mediated deletion of the CB1 gene
[27]. However, overlapping deletions are also present between
different lines. In Figure 3, a schematic representation of the
patterns of expression of the different lines is shown.
Locomotion. In all mutant lines examined, vehicle-treated
wild-type mice showed no signiﬁcant difference in locomotor
activity as compared to the respective mutant littermates
(GABA-CB1
þ/þ, 3585 6 206 cm versus GABA-CB1
 /  , 3708 6
195 cm; CaMK-CB1
þ/þ, 3339 6 110 cm versus CaMK-CB1
 /  ,
3022 6 182 cm; Glu-CB1
þ/þ, 3642 6 336 cm versus Glu-CB1
 / 
, 4124 6 507 cm; D1-CB1
þ/þ, 3403 6 239 cm versus D1-CB1
 / ,
3602 6 328 cm, p . 0.05 for all comparisons; n ¼ 9–10 for
each group), indicating that, in our test conditions, genetic
deletion of CB1 did not alter basal locomotor activity of mice.
Surprisingly, speciﬁc deletion of CB1 in GABAergic
neurons did not alter the effect of THC on locomotion.
Indeed, THC strongly reduced locomotion in both wild-type
GABA-CB1
þ/þ and conditional mutant GABA-CB1
 /  mice (p
, 0.0001 Figure 4A), without any signiﬁcant difference
between genotypes (interaction genotype 3 treatment, F1,55
¼ 1.66, p ¼ 0.204; Figure 4A). To reveal more subtle
differences between genotypes, we performed further experi-
ments in which a lower dose of THC was used. Also at the
dose of 3 mg/kg, no signiﬁcant difference was observed
between genotypes (two-way analysis of variance [ANOVA],
Figure S1A and Text S1).
Conversely, in mice lacking CB1 from all principal neurons
but still expressing the receptor in a majority of cortical
GABAergic interneurons, the hypolocomotor effect of THC
was strongly and signiﬁcantly reduced (Figure 4B). THC
decreased locomotion both in CaMK-CB1
þ/þ (p , 0.001;
Figure 4B) and in CaMK-CB1
 /  mice (p , 0.05; Figure 4B).
However the effect of THC was signiﬁcantly reduced in the
mutant mice as compared to wild-type littermates (inter-
action genotype3treatment, F1,36¼12.5, p¼0.001; Figure 4B)
Together, the results obtained in GABA-CB1
 /  and CaMK-
CB1
 /  suggest that the expression of CB1 in GABAergic
neurons is not sufﬁcient to exert the effects of THC on
locomotor activity, and the results indicate that other
neuronal populations must be involved. Interesting candi-
dates for this function are CB1 receptors present in cortical
glutamatergic neurons, which project to basal ganglia and
Figure 4. Effect of THC on Locomotor Activity of Different CB1 Mutant Mice
Horizontal locomotor activity was recorded for 15 min, 60 min after the injection of 10 mg/kg THC or vehicle. Values were recorded in cm and
normalized to vehicle-treated wild-type animals of each mutant line (100%). *, **, ***; p , 0.05, p , 0.01, p , 0.001, respectively. (two-way ANOVA,
followed by Newman-Keuls post-hoc test). Note the normal effect of the drug in GABA-CB1
 /  (A), the impaired effect in CaMK-CB1
 /  (B), and in Glu-
CB1
 /  (C), and the normal effect in D1-CB1
 /  mice (D). For D1-CB1
 / , see text for a slight impairment in the relative effect of THC. See Materials and
Methods for number of animals in each group.
doi:10.1371/journal.pbio.0050269.g004
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Effects of THC in Conditional CB1 Mutantsthereby likely regulate locomotor activity [42,43]. CaMK-
CB1
 /  mice are not the ideal model for testing this
hypothesis, because in this mouse line, CB1 is absent from
all forebrain principal neurons (expressing CaMKIIa) [44],
which include cortical glutamatergic neurons and also
subcortical projecting neurons in the basal ganglia, thalamus,
and hypothalamus [27]. Therefore, we tested the effects of
THC in Glu-CB1
 /  mice, which lack CB1 expression
Figure 5. Effect of THC on Body Temperature of Different CB1 Mutant Mice
Body temperature was measured with an infrared thermometer before injection (see text), 1 h (left panels) and 2 h (right panels) after the injection of 10
mg/kg of THC or vehicle. Values represent the difference of the body temperature of each animal with the mean of the respective vehicle-treated
animals. *, **, ***; p , 0.05, p , 0.01, p , 0.001, respectively (two-way ANOVA, followed by Newman-Keuls post-hoc test). Note that THC has a normal
effect in GABA-CB1
 /  (A), but impaired (weaker and/or short lasting) effect in CaMK-CB1
 /  (B), in Glu-CB1
 /  (C), and in D1-CB1
 /  mice (D). See
Materials and Methods for number of animals in each group.
doi:10.1371/journal.pbio.0050269.g005
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Effects of THC in Conditional CB1 Mutantsspeciﬁcally in cortical glutamatergic neurons, but not in
subcortical regions [27,45]. Similarly to its effect on CaMK-
CB1
 /  mice, THC was able to reduce locomotion both in
wild-type Glu-CB1
þ/þ mice (p , 0.001; Figure 4C) and Glu-
CB1
 /  littermates (p , 0.01; Figure 4C). However, a
signiﬁcantly lower effect of THC in the mutant mice was
observed as compared to wild-type controls (p , 0.05, Figure
4C). Further comparison of the relative effects of THC in
CaMK-CB1
 /  (to 75.4% 6 9% of respective vehicle-treated
mice) and Glu-CB1
 /  mice (41.2% 6 12% of respective
vehicle-treated mice) revealed no signiﬁcant difference
between the two mutant lines (p . 0.05, Student’s t-test),
suggesting that CB1 expression in glutamatergic cortical
neurons might be a major site mediating the pharmacological
effect of THC.
The hypolocomotor effect of THC does not appear to be
signiﬁcantly inﬂuenced by expression of CB1 receptors in
dopamine receptor D1-containing neurons. The strong effect
of THC in wild-type D1-CB1
þ/þ mice was also present in
mutant D1-CB1
 /  littermates (p , 0.001 for both genotypes,
Figure 4D), with no signiﬁcantly different effect in the two
genotypes (interaction genotype 3 treatment F1,27 ¼ 0.8, p ¼
0.390). However, although not revealed by two-way ANOVA, a
comparison of the relative effects of THC in both genotypes
revealed a slight difference between D1-CB1
þ/þ(4.4% 6 1.2%)
and D1-CB1
 /  (10.1% 6 1.3 % of respective vehicle-treated
mice; p,0.01, t-test), suggesting that THC was slightly less
effective in mutant mice.
Body temperature. No signiﬁcant differences were ob-
served by comparing basal body temperature (before in-
jection of THC or vehicle) of mutant mice with their
respective wild-type littermates (GABA-CB1
þ/þ, 33.2 6 0.2 8C
versus GABA-CB1
 /  , 33.4 6 0.18C; CaMK-CB1
þ/þ, 35.0 6
0.18C versus CaMK-CB1
 /  , 35.0 6 0.18C; Glu-CB1
þ/þ, 33.9 6
0.18C versus Glu-CB1
 / , 34.0 6 0.2 8C; D1-CB1
þ/þ, 34.1 6
0.28C versus D1-CB1
 /  , 33.7 6 0.18C; n ¼ 14–32 for each
group; p . 0.05 for all comparisons).
Deletion of CB1 in GABAergic neurons did not alter the
effect of THC, with the body temperature of both GABA-
CB1
þ/þ and GABA-CB1
 / littermates signiﬁcantly dropping as
compared to respective vehicle-treated controls 1 h and 2 h
after injection (p , 0.05), without any signiﬁcant difference in
the drug effect between genotypes (1 h, interaction genotype
3 treatment, F1,57 ¼ 0.46, p ¼ 0.499; 2 h, interaction genotype
3treatment, F1,56¼0.0, p¼0.987; Figure 5A). A lower dose of
THC was also tested on these mice in a dose-response
experiment. Under these conditions as well, the effects of
THC were not signiﬁcantly different between genotypes at
both time points after treatment (two-way ANOVA; Figure
S1C and S1D, Text S1).
In contrast, the effect of THC was strongly impaired in
mice lacking CB1 in principal neurons. In fact, whereas the
drug decreased the body temperature of wild-type CaMK-
CB1
þ/þ mice (1 h, p , 0.001 versus vehicle-treated controls; 2
h, p , 0.001, Figure 5B), it failed to exert any signiﬁcant effect
on mutant CaMK-CB1
 /  littermates (1 h, p . 0.05; 2 h, p .
0.05 versus vehicle-treated controls), resulting in a signiﬁcant
genotype 3 treatment interaction at both time points after
THC injection (1 h, F1,36¼19.8, p , 0.0001; 2 h, F1,36¼6.1, p ,
0.018; Figure 5B). Similarly to locomotion data, these results
indicate that principal neurons, but not GABAergic neurons,
mediate the hypothermic effects of THC in mice.
Figure 6. Analgesic Effect of THC in Different CB1 Mutant Mice
Latency to show signs of discomfort on a 55 8C hot plate was measured 75 min after the injection of 10 mg/kg THC or vehicle. A 60-s cut-off time was
applied. *, **, ***; p , 0.05, p , 0.01, p , 0.001, respectively (two-way ANOVA, followed by Newman-Keuls post-hoc test). Note that THC has a normal
effect in GABA-CB1
 /  (A), in Glu-CB1
 /  (C) and D1-CB1
 /  mice (D), but no effect in CaMK-CB1
 /  mice (B). See Materials and Methods for number of
animals in each group.
doi:10.1371/journal.pbio.0050269.g006
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Effects of THC in Conditional CB1 MutantsGlutamatergic transmission has been implicated in canna-
binoid-induced hypothermia [46]. Therefore, a direct regu-
lation of CB1-expressing cortical glutamatergic afferents
might be responsible of the hypothermic effect of THC.
Indeed, mutant mice lacking CB1 expression in cortical
glutamatergic neurons showed a reduced and shorter-lasting
response to the hypothermic effect of 10 mg/kg THC. One
and two hours after THC injection, wild-type Glu-CB1
þ/þmice
presented a signiﬁcant reduction in body temperature as
compared to vehicle-injected controls at both time points (p
, 0.001, Figure 5C), whereas mutant Glu-CB1
 /  littermates
showed a lower effect, which did not reach statistical
signiﬁcance as compared to respective vehicle-injected
controls (p . 0.05, Figure 5C). Two-way ANOVA revealed
that this situation resulted in a reduction of the drug effect in
the mutant mice, which reached statistical signiﬁcance 2 h
after THC injection (interaction genotype3treatment F1,34¼
5.4, p ¼ 0.026; Figure 5C). Further comparison of the relative
effect of THC in CaMK-CB1
 /  and Glu-CB1
 /  mice revealed
no signiﬁcant difference at either time point after injection
(1 h, p ¼ 0.3; 2 h, p ¼ 0.5), indicating that these two mutant
mouse line present a similarly impaired response to hypo-
thermic effects of THC. Altogether, these data strongly
indicate that glutamatergic cortical neurons are centrally
involved in the hypothermic effects of THC in mice.
Dopamine transmission has been proposed to be involved
in the regulation of body temperature [47,48] and to regulate
hypothermic effects of THC [49]. Therefore, it is possible that
the presence of CB1 in dopamine D1 receptor-expressing
neurons contributes to the hypothermic effects of THC. The
drug induced a signiﬁcant decrease of body temperature both
in wild-type D1-CB1
þ/þ and mutant D1-CB1
 /  littermates at
both time points (p , 0.01; Figure 5D). However, the effect
appeared to be reduced in mutant mice, reaching a
signiﬁcant difference 2 h after drug injection (interaction
genotype 3 treatment F1,27 ¼ 5.78, p ¼ 0.024; Figure 5D),
indicating a lower and shorter lasting effect of THC in the
mutant mice.
Nociception
Deletion of CB1 in GABAergic neurons did not alter the
analgesic effect of THC. Neither baseline hot-plate escape
latencies after vehicle injection (Figure 6A, p . 0.05) nor
THC-induced analgesia showed any signiﬁcant difference
between wild-type GABA-CB1
þ/þ and mutant GABA-CB1
 / 
littermates (interaction genotype 3 treatment F1,57 ¼ 1.7, p ¼
0.204; Figure 6A). Identical results were obtained with a lower
dose of THC (3 mg/kg), which was also unable to induce
signiﬁcantly different effects between genotypes (two-way
ANOVA; Figure S1B and Text S1). Therefore, CB1 receptors
that are expressed in GABAergic neurons do not appear to
play a signiﬁcant role in THC-induced analgesia.
Vehicle-treated CaMK-CB1
 /  did not show any difference
in escape latency as compared to vehicle-treated control wild-
type littermates (Figure 6B). Conversely, wild-type CaMK-
CB1
þ/þ mice showed normal sensitivity to the analgesic effect
of THC (p , 0.001; Figure 6B), whereas the mutant littermates
CaMK-CB1
 /  did not respond to the injection of the
cannabinoid drug (p . 0.05; Figure 6B), as shown by a highly
signiﬁcant genotype3treatment interaction (F1,36¼17.9, p ,
Figure 7. Cataleptic Effect of THC in Different CB1 Mutant Mice
Latency of descent of the forepaws from a horizontal bar was recorded for 20 s, 90 minutes after the injection of 10 mg/kg THC or vehicle. *, **, ***;
p , 0.05, p , 0.01, p , 0.001, respectively (two-way ANOVA, followed by Newman-Keuls post-hoc test). The effect is preserved in GABA-CB1
 / (A) and
Glu-CB1
 /  mice (C), but almost completely abolished in CaMK-CB1
 /  (B) and D1-CB1
 /  mice (D). See Materials and Methods for number of animals in
each group.
doi:10.1371/journal.pbio.0050269.g007
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Effects of THC in Conditional CB1 Mutants0.001; Figure 6B). These data indicate that principal neurons
expressing CB1 receptors play a central role in the analgesic
effect of THC.
However, at odds with locomotor and hypothermic effects
of THC, cortical glutamatergic neurons do not appear to
contribute to the analgesic effect of THC. In fact, the normal
effect of the drug observed in wild-type Glu-CB1
þ/þ was
present also in mutant Glu-CB1
 /  (Figure 6C) with no
difference between genotypes (interaction genotype 3 treat-
ment, F1,33 ¼ 0.1, p ¼ 0.772), indicating that CB1-postive
principal neuronal populations outside of the neocortex are
likely involved in these effects of THC.
The deletion of CB1 receptors in dopamine receptor D1-
expressing neurons also did not alter the analgesic effects of
THC. The drug exerted analgesic effects in both D1-CB1
þ/þ
and D1-CB1
 /  littermates (p , 0.01; Figure 6D), without any
signiﬁcant difference between genotypes (interaction geno-
type 3 treatment, F1,27 ¼ 0.5, p ¼ 0.483), indicating that CB1
expressed in the majority of striatal neurons and in layer VI
of neocortex are unlikely to mediate this effect of THC.
Catalepsy
THC-induced catalepsy was normally present in both
GABA-CB1
þ/þ and GABA-CB1
 /  mice (p , 0.01 and p ,
0.001, respectively, Figure 7A), without any difference
between genotypes (statistics not shown). A dose-response
study conﬁrmed the lack of statistically signiﬁcant difference
between the cataleptic effects of THC in the two groups of
mice (two-way ANOVA, Figure S1E and Text S1). Conversely,
the cataleptic effect of 10 mg/kg THC could be observed in
CaMK-CB1
þ/þ (p , 0.001; Figure 7B), but not in CaMK-CB1
 / 
mice (p . 0.05; Figure 7B). Two-way ANOVA revealed a
highly signiﬁcant difference in the effect of THC between the
two genotypes (interaction genotype3treatment, F1,36¼44.6,
p , 0.0001), indicating the dependency of this effect of THC
on principal neurons. However, deletion of CB1 from
glutamatergic cortical neurons is not sufﬁcient to impair
the cataleptic effect of THC. In fact, Figure 7C shows that the
drug was able to induce the effect both in Glu-CB1
þ/þ and in
Glu-CB1
 /  without any signiﬁcant interaction between treat-
ment and genotype (statistics not shown). Interestingly, 10
mg/kg THC did induce a strong cataleptic effect in D1-CB1
þ/þ
mice (p , 0.001; Figure 7D), whereas D1-CB1
 /  mice were
insensitive to this action (p . 0.05; interaction genotype 3
treatment, F1,31 ¼ 55.9, p , 0.0001; Figure 7D). Thus,
GABAergic neurons and cortical glutamatergic neurons do
not appear to play a central role in this effect, whereas
principal neurons expressing D1 receptors appear to mediate
THC-induced catalepsy.
Discussion
The present study addressed the neuronal circuits media-
ting some of the most common effects of cannabinoids in
mice, the so-called ‘‘tetrad’’ battery of effects [3,4]. To this
aim, we used a combined genetic and pharmacological
approach and analysed the effects of THC in previously
described CB1 conditional mutant mice [26,27] and in newly
generated mice, which lacked CB1 expression in the majority
of striatal MSNs and a subset of glutamatergic neurons in
layer VI of the neocortex. Taken together (Table 2 and Figure
8), our genetic and pharmacological results show that (1)
various pharmacological effects of cannabinoids are medi-
ated by different neuronal circuits, which can be dissected by
genetic approaches; (2) GABAergic interneurons do not
appear to mediate these effects of THC; (3) cortical
glutamatergic neurons mediate a large portion of hypoloco-
motor effects of cannabinoids; (4) similarly, CB1 expression
in cortical glutamatergic neurons plays a prominent role in
mediating the hypothermic effects of THC, with a possible
partial involvement of a subpopulation of MSNs; (5) the
simultaneous activation of CB1 receptors located on striatal
neurons and glutamatergic neocortical neurons is likely to be
necessary to exert the cataleptic effect of THC; and (6)
analgesic effects depend on principal neurons of the central
nervous system, but their precise identity is not yet clearly
identiﬁable.
Methodological aspects have to be considered in these
experiments. CB1 cannabinoid receptors are widely ex-
pressed in the central nervous system and, importantly, are
present in different neuronal subpopulations [11,17,24,25,50].
This study was undertaken with the aim to dissect important
pharmacological effects of THC with respect to their cellular
mechanisms and, in particular, to the differential involve-
ment of distinct neuronal subpopulations in these effects. To
address this issue, we used conditional mutagenesis, and our
results were able to identify several likely sites of action of
THC in the brain. However, genetic manipulations are not
free of possible confounding issues [51]. Indeed, deletion of a
gene by gene targeting (although in a conditional manner)
could lead to compensatory mechanisms, which might cause
misleading interpretations. Moreover, the use of speciﬁc
regulatory sequences to drive the expression of Cre recombi-
nase is not devoid of caveats, because the Cre-induced
Table 2. Summary of the Results of THC Treatment in Different CB1 Mutant Lines
Mutant Line Locomotion Body Temperature Nociception Catalepsy
Wild-type Normal effect Normal effect Normal effect Normal effect
CB1
 /  No effect No effect No effect No effect
GABA-CB1
 /  Normal effect Normal effect Normal effect Normal effect
CaMK-CB1
 /  Decreased effect No effect No effect No effect
Glu-CB1
 /  Decreased effect Decreased effect (shorter) Normal effect Normal effect
D1-CB1
 /  Normal effect (slightly decreased) Decreased effect (shorter) Normal effect No effect
Normal effect refers to decrease of spontaneous locomotor activity (column ‘‘locomotion’’), drop of body temperature (column ‘‘body temperature’’), increase of the threshold of thermal
nociception (column ‘‘nociception’’), and duration of catalepsy (column ‘‘catalepsy’’).
doi:10.1371/journal.pbio.0050269.t002
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Effects of THC in Conditional CB1 Mutantsrecombination pattern might be different from the expected
one, based on the known cell types where the regulatory
sequences are supposed to drive Cre expression. For instance,
the Nex-Cre mice used to generate Glu-CB1
 /  mice, besides
showing the expected recombination in cortical glutamater-
gic neurons, also showed a small degree of recombination in
other neurons. The other neurons, however, likely contain
very low, if any, expression of CB1 receptors [45]. Never-
theless, conditional mutagenesis is the only tool available to
date to dissect with a high degree of precision the role of a
given gene in different neuronal populations, and our results,
though surprising to a certain extent, ﬁt with other data and
concepts present in the literature and, importantly, are
conﬁrmed by the parallel analysis of several complementary
conditional CB1 mutant mouse lines.
The persistence of the ‘‘tetrad’’ effects of THC in mice
lacking CB1 receptors in GABAergic neurons (Table 2, Figure
8) is surprising. Due to the extremely high levels of CB1
receptors present on cortical GABAergic interneurons, the
current hypothesis has been that this neuronal population
might mediate most of the effects of exogenously applied or
endogenously released (endo)cannabinoids [23]. The lack of
THC effects is unlikely to be caused by developmental or
compensatory effects of the lack of CB1 in GABAergic
neurons in GABA-CB1
 /  mice [52] for the following reasons.
First, the same effects of THC are abolished in CaMK-CB1
 / 
and partially reduced in Glu-CB1
 /  mice, which still express
CB1 in GABAergic interneurons. Second, another important
function of CB1 receptors, i.e., the physiological protection
against excitotoxic seizures induced by kainic acid, was
recently shown to be preserved in GABA-CB1
 /  mice and
strongly impaired in CaMK-CB1
 /  and Glu-CB1
 /  mice [27].
Third and importantly, our previous data show that physio-
logical retrograde release of endocannabinoids that act at
CB1 receptors expressed in hippocampal GABAergic termi-
nals, mediating short-term forms of synaptic plasticity
(depolarization-induced suppression of inhibition, DSI), is
abolished in GABA-CB1
 /  mice [27], thereby indicating that
these mice indeed lack functional expression of CB1
receptors. The overall normal pharmacological effects of
THC in GABA-CB1
 /  mice, accompanied by the absence of
DSI, and the strong reduction of the ‘‘tetrad’’ effects in
CaMK-CB1
 /  and Glu-CB1
 /  mice, accompanied by normal
expression of DSI [27], show that these particular endocan-
nabinoid-dependent electrophysiological phenomena are not
involved in the ‘‘tetrad’’ pharmacological effects of cannabi-
noids. These results then suggest that other effects of CB1
activation, such as depression of glutamatergic transmission,
might play a more relevant role in this context.
Cannabinoids can control glutamatergic transmission via
CB1 receptors in several brain regions [28,53–56]. Recently,
using GABA-CB1
 /  and CaMK-CB1
 / , we could conﬁrm that
exogenous application of cannabinoids controls glutamater-
gic transmission through CB1 receptors present on gluta-
matergic neurons of the amygdala, the hippocampus, and the
neocortex [27,29]. Therefore, it is possible that control of
glutamatergic transmission represents the most important
neuronal mechanism underlying ‘‘classical’’ effects of canna-
binoids in mice. In particular, hypolocomotor and hypo-
thermic effects of THC appear to depend to a large extent on
the functional expression of CB1 on cortical glutamatergic
neurons, because they are strongly reduced both in CaMK-
Figure 8. Graphic Representation of Results Obtained with Different CB1 Mouse Mutant Lines
Overlapping of CB1 deletion in the different mutant lines is represented as in Figure 3. Patterned areas represent the likely regions and/or cell types
where THC exert its effects on (A) locomotion (principal glutamatergic cortical neurons), (B) body temperature (principal glutamatergic cortical neurons
with a possible participation of a portion of striatal MSNs), (C) pain perception (principal neurons, but not striatal MSNs nor glutamatergic cortical
neurons), and (D) catalepsy (principal neurons, likely by a simultaneous stimulation of CB1 receptors on both MSNs and glutamatergic cortical neurons).
Note that GABAergic interneurons (represented by the nonoverlapping portion of the red circle) never appear to be necessary for any of the observed
THC effects.
doi:10.1371/journal.pbio.0050269.g008
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 /  and in Glu-CB1
 /  mice (Table 2). In particular,
corticostriatal glutamatergic projection neurons might in-
deed represent the main site of action of THC to induce
hypolocomotor effects (Figure 8A) by reducing the excitatory
input onto basal ganglia, as previously shown by electro-
physiological recordings [43]. Striatal neurons, being GA-
BAergic principal neurons, are depleted of CB1 expression
both in GABA-CB1
 /  mice (where THC has a normal effect
on locomotion) and in CaMK-CB1
 /  mice (where the
hypolocomotor effect is strongly reduced). Given the strong
impairment of this effect in Glu-CB1
 /  mice (which express
normal levels of CB1 mRNA in the striatum) [27], the
presence of CB1 protein in corticostriatal glutamatergic
neurons appears as a plausible candidate to mediate the
hypolocomotor effects of THC in mice. To verify this
hypothesis, we used mice lacking CB1 expression in the
majority of striatal neurons (D1-CB1
 /  mice). In these mice,
the effect of THC was only very slightly reduced. It is,
therefore, possible that a subpopulation of striatal neurons
partially contribute to the hypolocomotor effect of THC.
However, D1-CB1
 /  mice lack CB1 also in a subgroup of
pyramidal neurons in the layer VI of neocortex. Given the
normal effect of THC in GABA-CB1
 /  mice, which lack CB1
in the totality of striatal neurons, but still express normal
levels in pyramidal cortical neurons, the most parsimonious
interpretation of the data taken as a whole is that the absence
of CB1 in layer VI pyramidal neurons of the neocortex likely
accounts for the slight reduction of hypolocomotor effect of
THC in D1-CB1
 /  mice (Figure 8A). However, although
striatal projections have been described [57], layer VI
pyramidal neocortical neurons project mainly to thalamic
regions and their possible function in control of locomotion
has been proposed but is still not fully elucidated [58,59]. It is
important to note that the hypolocomotor effect of THC in
CaMK-CB1
 / , Glu-CB1
 / , and D1-CB1
 /  is not completely
abolished in any of the three lines. This might be due to
residual expression of CB1 in other brain regions. For
instance, cerebellar neurons are not affected by Cre-
mediated recombination in either of the lines [27] (Figure
2). Given the importance of this brain region in controlling
locomotion, it is very likely that the conserved expression of
CB1 in the cerebellum accounts for the portion of main-
tained effect of THC.
Concerning hypothermic effects, a pharmacological syn-
ergy between N-methyl-D-aspartic acid (NMDA) glutamate
receptor antagonists and cannabinoids was recently shown in
rats [46]. Therefore, inhibition of glutamatergic transmission
is a likely mechanism of THC-dependent hypothermia.
Moreover, the preoptic anterior hypothalamic nucleus has
been proposed to mediate the hypothermic effects of
cannabinoids, where they likely regulate glutamatergic trans-
mission [60] (and references inside). Therefore, our data, by
showing that hypothermic effects of THC are reduced in
CaMK-CB1
 /  and Glu-CB1
 /  (Table 2 and Figure 8B), are in
agreement with the notion that a CB1-dependent reduction
of glutamatergic transmission (possibly at the level of cortico-
hypothalamic projections) is the main mechanism of THC-
induced hypothermic effects. The reduced and shorter lasting
effect of THC in D1-CB1
 / mice is more difﬁcult to interpret.
On the one hand, the absence of CB1 expression from a
subpopulation of glutamatergic neurons of neocortical layer
VI might account for the phenotype of these mutant mice.
However, a very recent publication suggested that the
hypothermic effect of THC and its neuroprotective con-
sequences during cerebral infarction might rely on CB1
expressed in cortical and striatal regions [61]. This suggests
that speciﬁc striatal neurons might participate in the hypo-
thermic effects of THC.
Hypoalgesic effects of THC, although likely independent
from GABAergic interneurons, do not appear to depend on
CB1 expressed on cortical glutamatergic neurons nor on
striatal neurons, because they are normally present in Glu-
CB1
 /  and D1-CB1
 /  mice, respectively (Table 2, Figure 8C).
The exact determination of the neuronal circuitries and the
brain regions responsible for each single effect of cannabi-
noids will require further studies using even more sophisti-
cated experimental approaches, such as viral-induced cell-
type–speciﬁc deletion of the CB1 gene. However, the present
data already allow some speculation. For analgesic effects,
regions such as the periaqueductal grey might play an
important role [19,62–64]. However, given the relatively low
levels of CB1 expression in these regions of the central
nervous system, it is difﬁcult to evaluate the possible lack of
expression of CB1 receptors in CaMK-CB1
 /  mice, which do
not show THC-induced hypoalgesia. Nevertheless, our data
clearly show that GABAergic neurons are not implicated in
this effect. Moreover, it is possible that hypoalgesic effects of
cannabinoids depend on the expression of CB1 at spinal sites
and/or even in peripheral neurons [19,64,65]. Indeed, recent
data clearly showed that conditional deletion of the CB1 gene
in peripheral neurons strongly reduces analgesic effects of
cannabinoid drugs [65]. In addition, interaction with nora-
drenergic neurons in the spinal cord might be a mechanism
of THC-induced hypoalgesia [66]. Therefore, given the wide
expression of CaMKIIa at several sites (likely including also
spinal and peripheral neurons), the lack of hypoalgesic effect
of THC in CaMK-CB1
 /  cannot, at the moment, be ascribed
to a precise location in the complex pathways mediating pain
perception.
Cataleptic effects of THC are impaired both in CaMK-
CB1
 /  and in D1-CB1
 /  mice (Table 2, Figure 8D). The basal
ganglia are involved in the adjustment and ﬁne tuning of
voluntary movements through two major pathways: the D1-
type dopamine receptor-containing direct and the D2-type
dopamine receptor-containing indirect pathways [42]. Inter-
estingly, catalepsy can be observed by pharmacological
manipulation of both pathways, and its exact mechanisms
are not yet understood in detail [67–69]. Moreover, catalepsy
is one of the hallmark effects of treatments, such as 6-OHDA
and reserpine, that are able to induce parkinsonian symp-
toms in animals [56]. In CaMK-CB1
 / mice, CB1 receptors are
lost in all projecting neurons of the brain, thus making it
difﬁcult to deﬁne the exact site of action of THC to induce
catalepsy. However, noradrenergic and serotonergic path-
ways (involving 5HT1a receptors) were proposed to play a
role in THC-induced catalepsy [70,71]. Noradrenergic and
serotonergic neurons likely express very low, but signiﬁcant
levels of CB1 [72,73]. As these neurons are principal
projecting neurons, it is possible that they lack CB1
expression in CaMK-CB1
 / . Thus, lack of THC-induced
control of serotonergic and/or noradrenergic transmission
might participate in the phenotype of CaMK-CB1
 / . In the
D1-CB1
 /  mice, on the other hand, most incoming striatal
afferents from cortex and thalamus still express CB1 normally
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MSNs of the direct pathway (traditionally considered as D1-
positive) [57] lack CB1 receptors, together with a certain
amount of putative neurons belonging to the D2-positive
subpopulation (believed to constitute the indirect pathway).
Therefore, cannabinoid treatment cannot affect GABA
release at the output sites in the globus pallidus and the
substantia nigra. Yet, GABA-CB1
 /  mice, lacking CB1 from
a l lG A B A e r g i cn e u r o n s( i n c l u d i n ga l ls t r i a t a lp r i n c i p a l
neurons) express catalepsy normally after THC treatment.
Cannabinoid-induced catalepsy, therefore, is produced most
probably by a simultaneous disturbance at more than one site
in the basal ganglia motor pathway. In this regard, the lack of
CB1 from a subgroup of pyramidal neurons in the neo-
cortical layer VI of D1-CB1
 /  mice might be particularly
interesting. Indeed, it is possible to speculate that the
simultaneous action of THC at CB1 receptors expressed
both in layer VI cortical neurons and in D1-expressing MSNs
is necessary to exert the typical cataleptic effect of the drug.
In this frame, the presence of CB1 in cortical glutamatergic
neurons of GABA-CB1
 /  mice would be sufﬁcient to exert
the normal cataleptic effect of THC. Interestingly, MSNs
belonging to the direct and indirect pathways were recently
shown to be differentially regulated by endocannabinoids,
and this phenomenon might have a particular importance in
the pathophysiology of Parkinson disease [56]. Therefore, it
will be very interesting to explore the phenotype of D1-CB1
 / 
in models of this disease, in order to start dissecting the loci
where cannabinoid-based therapy might be useful in the
treatment of this important neurological disorder [15,18,42].
The ‘‘tetrad’’ battery of effects does not represent the
myriad pharmacological functions of cannabinoids, ranging
from effects on learning [74,75], stress responses [12,75],
neuroendocrine and energy balance [12], reward [76], and
many others [15]. However, the fact that it is now possible to
dissect each of these effects will pave the way to a novel
concept of cannabinoid pharmacology and to new insights
into its mechanisms. This might also include the future
possibility for therapeutic targeting of speciﬁc cannabinoid
effects exerted in distinct neuronal subpopulations. It is
becoming more and more evident that CB1 receptors
physically interact with speciﬁc proteins in different neuro-
nal populations and that these interactions are able to modify
their pharmacological proﬁle [77–80]. Therefore, it will be
possible in the future to identify cannabinoid ligands that are
able to interact with CB1 receptors speciﬁcally coupled or
uncoupled with other proteins and, thereby, expressed in
different populations. The use of these drugs and the precise
determination of the sites of action of cannabinoids for
different effects might provide the opportunity to exploit
better the therapeutic potentials of cannabinoids, avoiding
possible undesirable side effects.
Materials and Methods
Animals. Male mice, aged 2–5 mo, were used in all experiments,
maintained in standard conditions with food and water ad libitum.
All experimental procedures were approved by the Committee on
Animal Health and Care of the local government. Conditional CB1
mutant mice were obtained by using the Cre/loxP system [31]. The
respective Cre-expressing mouse line was crossed with CB1f/f mice
[26], using a three-step breeding protocol. CaMK-CB1
 / , Glu-CB1
 / ,
and GABA-CB1
 /  mice were obtained as described [26,27]. Genotyp-
ing was performed by PCR as described for CaMK-CB1
 /  and for
CB1
f/f [26]. For the GABA-CB1
 /  line, genotyping for the Cre
transgene was performed by PCR using the following primers:
forward 59- GAT CGC TGC CAG GAT ATA CG; reverse: 59 - CAT
CGC CAT CTT CCA GCA G, whereas genotyping for the CB1
f/f locus
was performed as described [26]. CB1
þ/þ and CB1
 /  mice were
generated and genotyped as described [35]. All lines were in a mixed
genetic background, with a predominant C57BL/6NCrl contribution.
All animals used in single experiments were littermates. Experi-
menters were always blind to genotype and treatment.
The abbreviations used to identify the different mutants and their
wild-type littermates are summarized in Table 1.
Generation of D1-CB1
 /  mice. To generate the D1-CB1
 /  line
(Figure 1), CB1
f/f mice [26] were crossed with dopamine receptor D1-
Cre line [36,37], in which the Cre recombinase was placed under the
control of the dopamine receptor D1A gene (Drd1a) regulatory
sequences using transgenesis with modiﬁed bacterial artiﬁcial
chromosomes. The pattern of Cre expression recapitulated the
expression pattern of the endogenous Drd1a [36,37]. Genotyping for
the Cre transgene was performed by PCR using the following primers:
forward 59- GAT CGC TGC CAG GAT ATA CG; reverse: 59 - CAT
CGC CAT CTT CCA GCA G, whereas genotyping for the CB1
f/f locus
was performed as described [26].
Drugs. D
9-tetrahydrocannabinol (THC, Sigma-Aldrich; http://www.
sigmaaldrich.com) was purchased as a 10 mg/ml (w/v) solution in 100%
ethanol. This solution was concentrated to 100 mg/ml using a
SpeedVac and, immediately before injection, mixed with Tween 80,
and then diluted with 0.9% saline and shaken for 10 min at 37 8C.
Vehicle control contained all ingredients (1 drop / 3 ml of Tween 80
and ethanol diluted 1:40 with saline) except D
9-THC. Drug/vehicle was
administered intraperitoneally with an injection volume of 10 ml/kg
body weight. For behavioural tests, mice of each genotype received
different doses of THC or vehicle, as previously described [4,81].
Behavioural tests. To determine the effects of THC the following
number of animals were used in the experiments (Veh indicates
vehicle): GABA-CB1
þ/þ-Veh, 10; GABA-CB1
þ/þ-THC, 19; GABA-CB1
 / -
Veh, 10; GABA-CB1
 / -THC, 20; CaMK-CB1
þ/þ-Veh, 9; CaMK-CB1
þ/þ-
THC, 10; CaMK-CB1
 / -Veh, 10; CaMK-CB1
 / -THC, 11; Glu-CB1
þ/þ-
Veh, 9; Glu-CB1
þ/þ-THC, 10; Glu-CB1
 / -Veh, 8; Glu-CB1
 / -THC, 9;
D1-CB1
þ/þ-Veh, 9; D1-CB1
þ/þ-THC, 9; D1-CB1
 / -Veh, 10; D1-CB1
 / -
THC, 11.
Animals were placed in a reversed dark/light cycle (light off 8 A.M.,
light on 8 P.M.) for at least 15 d before the experiments. All
behavioural tests were performed in the dark phase (between 10
A.M. and 3 P.M.) under dim red light illumination in the following
order. Basal body temperature was measured in all animals before
injection. One hour after the injection of THC or vehicle, temper-
ature was again measured and animals were placed in the open ﬁeld
to assess locomotion for 15 min. Immediately afterwards, the mice
were placed on the hot-plate test and analgesia was measured for
maximum of 60 s (see below). Mice returned to their home cage for
about 14 min and then catalepsy was tested. After returning to home
cage for another 13–14 min, the temperature was measured again (2 h
after drug injection).
Locomotor activity. Locomotion was measured 60 min after
injection of THC or vehicle by an automated open ﬁeld system
(box size 32332 cm; illumination of 0–10 lux, MOTION, TSE GmbH;
http://www.tse-systems.com). Animals were individually tested for 15
min. The cumulative horizontal distance the animals moved within
the box was recorded.
Analgesia. THC-induced analgesia was measured using a hot plate
analgesia meter (type 12801, Bachofer Laboratoriumsgera ¨te, Reutlin-
gen, Germany) 75 min after injection of the drug or the vehicle. The
plate was heated to 55 6 0.5 8C and the time until mice showed the
ﬁrst sign of discomfort (licking or ﬂinching of the paws or jumping on
the plate, here deﬁned as escape latency) was recorded. A cut-off time
of 60 s was set to prevent tissue damage.
Body temperature. Body temperature was measured immediately
prior, as well as 60 and 120 min after injection of drug or vehicle
using a C-1600 infrared thermometer (Linear Laboratories; http://
www.linearlabs.com), which was placed between the forepaws at a
distance of approximately 3 cm from the abdomen.
Catalepsy. THC-induced catalepsy was measured by the bar
catalepsy test 90 min after drug or vehicle injection. The forepaws
of mice were placed on a 1-cm-diameter bar ﬁxed horizontally at 3.5
cm from the bench surface. The descent latency was recorded for an
observation period of 20 s.
In situ hybridization. Single and double ISH was carried out as
previously described [24,82] using radioactive and nonradioactive
CB1- and radioactive dopamine receptor D2-speciﬁc riboprobes
[24,82], respectively. Counting of cells expressing CB1 in the VI layer
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þ/þ littermates was
carried out on single radioactive ISH experiments. Random regions
corresponding to the VI layer of neocortex (sensory-motor part, right
above the corpus callosum) were captured at 403 magniﬁcation.
Numbers were randomly assigned to the images, and an observer
(blind of the genotype of each single image) counted high CB1-
expressing neurons (corresponding to GABAergic interneurons and
deﬁned as in [24]) and low CB1-expressing neurons (belonging to
pyramidal glutamatergic cortical neurons) [27]. Numbers of low and
high CB1-expressing neurons per analyzed ﬁeld were calculated. For
CB1/D2 coexpressing neurons in the striatum, a similar approach was
used in double ISH slides. Numbers of single CB1-, single D2- and
double-expressing neurons were calculated.
Data analysis. Data are presented as mean 6 standard error of the
mean (SEM) of individual data points. Vehicle-mediated effects were
compared between genotypes in absolute values. For open ﬁeld, data
are expressed as percentages of vehicle-treated wild-type animals
(absolute data of vehicle-injected mice are reported in the text). Body
temperature data are expressed as differences from vehicle-treated
animals of the same genotype (deﬁned as DT in the ﬁgures), with
absolute values of vehicle-treated mice reported in the text. Data
were analysed using two-way ANOVA, using genotype and treatment
as variables, and Newman-Keuls post-hoc test. In some cases, to
appreciate differential effects of THC between different strains,
percentage ‘‘relative effects’’ of THC were calculated for each
genotype and analyzed with Student’s t-test. Graphs and statistics
were generated by GraphPad Prism 4.03 (GraphPad Software; http://
www.graphpad.com) and Statistica 5.0 (StatSoft; http://www.statsoft.
com), respectively.
Supporting Information
Figure S1. Dose-Response of THC Effects on GABA-CB1
þ/þ and
GABA-CB1
 /  Mice
Found at doi:10.1371/journal.pbio.0050269.sg001 (49 KB PDF).
Text S1. Materials and Methods Describing Figure S1
Found at doi:10.1371/journal.pbio.0050269.sd001 (30 KB DOC).
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